Does diastolic dysfunction precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy?
Diastolic dysfunction can precede systolic dysfunction on MUGA in patients receiving trastuzumab, offering an opportunity for early referral and management of cardiotoxicity.
Patients with normal diastolic function at baseline receiving trastuzumab±anthracycline adjuvant therapy may develop DD before SD, therefore offering an opportunity for early referral to cardiologists to optimize cardiovascular risk factors and manage cardiotoxicity.
Klein et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: